Bahrain has approved “Sotrovimab” for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19.
The decision to add “Sotrovimab” to COVID-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK’s clinical trials.
“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation.
Safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalisation for more than 24 hours and a reduction in the number fatalities by 85%, when administered at an early stage of treatment.
